Venture Capital

Following a chaotic power outage, unions and city leaders rally against Waymo, demanding answers on public safety, job security, and regulatory oversight.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Riding high on U.S. success, GEEK BAR returns to Europe with a reusable vape, a strategic pivot as the continent wages war on disposable products.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

A new DLA contract with REalloys seeks to onshore Samarium and Gadolinium production, vital for defense, using a breakthrough zero-waste technology.

Following strong shareholder support, Azimut Exploration launches a massive drilling campaign targeting deep gold potential and expanding known resources in Quebec.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

AI firm MiniMax reports a 159% revenue surge alongside a massive paper loss, revealing the strange economics of AI growth and its global ambitions.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

With its new AI thriller, muVpix is betting on 'engineered storytelling' to finally crack the vertical video code that doomed giants like Quibi.

Orca Energy moves a high-stakes $167M legal battle with the now-liquidated Swala Oil and Gas into private arbitration, raising questions for investors.

Digital pen inventor Anoto reports shrinking sales but better margins, leaning on a high-stakes loan to fuel its strategic reboot in a competitive market.

With key investor conferences looming, Asana is set to showcase its AI strategy. Can it convince Wall Street its vision will drive profit and beat rivals?